Dkk-4 Activators
The chemical class known as Dkk-4 Activators comprises a diverse spectrum of compounds carefully selected for their potential to modulate the activity of Dkk-4, a protein encoded by the DKK-4 gene. While specific direct activators may not be conclusively identified, these compounds operate through intricate interactions with the Wnt/β-catenin signaling pathway and associated cellular processes, suggesting a nuanced regulatory influence on Dkk-4 function. Actvators of this class inhibit GSK-3β and potentially activate Dkk-4 through the stabilization of β-catenin. Inhibition of GSK-3β distrupts the phosphorylation and subsequent degradation of β-catenin, allowing its accumulation. The stabilized β-catenin may then interact with Dkk-4, influencing Dkk-4 activation through modulation of the Wnt/β-catenin pathway. Similarly, activators promote Dkk-4 by stabilizing axin, a negative regulator of the Wnt pathway. Inhibition disrupts the degradation of axin, facilitating increased destruction complex formation. This mechanism may lead to the activation of the Wnt/β-catenin pathway, indirectly influencing Dkk-4 activation.
Furthermore, activators act on Dkk-4 by disrupting β-catenin-mediated transcriptional repression, indirectly influencing Dkk-4 activity. Activators can promote Dkk-4 by blocking GSK-3β-mediated phosphorylation and degradation of β-catenin. Lastly, activators operate through the modulation of intracellular calcium signaling, impacting cellular processes related to Dkk-4 activation. Collectively, the Dkk-4 activators constitute a chemically diverse group that intricately navigates the complexities of the Wnt/β-catenin pathway, shedding light on potential avenues for the regulation of Dkk-4 function within cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium, a GSK-3β inhibitor, can potentially activate Dkk-4 by preventing GSK-3β-mediated degradation. Inhibition of GSK-3β leads to the stabilization of β-catenin, which may interact with Dkk-4. This interaction could potentially activate Dkk-4 through modulation of the Wnt/β-catenin pathway. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
BIO is a GSK-3β inhibitor that can activate Dkk-4 by preventing GSK-3β-mediated phosphorylation and degradation of β-catenin. Inhibition of GSK-3β allows for the stabilization of β-catenin, potentially facilitating its interaction with Dkk-4 and leading to the activation of Dkk-4 through modulation of the Wnt/β-catenin pathway. | ||||||
Norcantharidin | 29745-04-8 | sc-280719 | 5 g | $113.00 | 2 | |
Norcantharidin activates the Wnt/β-catenin pathway, potentially influencing Dkk-4 activation. By inhibiting protein phosphatase 2A (PP2A), norcantharidin prevents the dephosphorylation of β-catenin, leading to its stabilization. The stabilized β-catenin may interact with Dkk-4, indirectly activating Dkk-4 through modulation of the Wnt pathway. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV-939, a tankyrase inhibitor, can activate Dkk-4 by stabilizing axin, a negative regulator of the Wnt/β-catenin pathway. Inhibition of tankyrase prevents the degradation of axin, leading to increased destruction complex formation. This may result in the activation of the Wnt/β-catenin pathway, influencing Dkk-4 activation. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC23766, an inhibitor of Rac1, may activate Dkk-4 by inhibiting the Rac1 signaling pathway. Inhibition of Rac1 can potentially influence cellular processes related to Dkk-4 activation, as Rac1 is involved in cytoskeletal remodeling and signaling cascades that may impact Dkk-4 function. | ||||||
Thiazovivin | 1226056-71-8 | sc-361380 sc-361380A | 10 mg 25 mg | $284.00 $634.00 | 15 | |
IWP-2 is a Wnt pathway inhibitor that can activate Dkk-4 by blocking Wnt secretion. Inhibition of Wnt secretion by IWP-2 may result in the stabilization of the destruction complex, preventing the degradation of β-catenin. This could potentially activate Dkk-4 through modulation of the Wnt/β-catenin pathway. | ||||||